{"nctId":"NCT04410328","briefTitle":"Aggrenox To Treat Acute Covid-19","startDateStruct":{"date":"2020-10-21","type":"ACTUAL"},"conditions":["Covid19"],"count":98,"armGroups":[{"label":"Participants receiving Dipyridamole and Aspirin","type":"EXPERIMENTAL","interventionNames":["Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care","Other: Standard of care"]},{"label":"Participants receiving standard of care","type":"OTHER","interventionNames":["Other: Standard of care"]}],"interventions":[{"name":"Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care","otherNames":["Aggrenox"]},{"name":"Standard of care","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Hospitalization.\n3. SARS-CoV-2 viral nucleic acid positive within 3 days.\n4. Lab test result pending plus a high clinical suspicion for SARS-CoV-2 (fever and cough for ≤ 7 days, bilateral pulmonary infiltrates on imaging or new hypoxemia with spO2 ≤94% on room air or no alternative explanation for respiratory symptoms).\n5. Willing and able to provide consent or by authorized proxy.\n\nExclusion Criteria:\n\n1. Pregnancy.\n2. G-6PD deficiency.\n3. Use of antiplatelet agents including inhibitor of P2Y12 ADP platelet receptors, phosphodiesterase inhibitors, and Glycoprotein IIB/IIIA inhibitors.\n4. On therapeutic anticoagulation with coumadin, heparin and direct oral anticoagulants.\n5. Vasodilatory shock.\n6. Patient with known ongoing angina, recent myocardial infarction and sub-valvular aortic stenosis.\n7. Active gastric or duodenal ulcer or any bleeding disorder.\n8. Hemoglobin \\<9 mg/dL, platelet count of \\<30,000 /mm3.\n9. Acute respiratory infection for \\>10 days.\n10. Known allergy/hypersensitivity to Dipyridamole and/or Aspirin.\n11. Severe hepatic or renal insufficiency.\n12. Uncontrolled hypertension defined as systolic \\> 180 mm Hg or diastolic \\> 100 mm Hg.\n13. Patients with known allergy to NSAIDs","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Covid (Coronavirus Disease-19) Ordinal Scale","description":"Change in composite COVID ordinal scale from day 1 to 14. Ordinal scale: 1) not hospitalized with resumption of normal activities; 2) not hospitalized, but unable to resume normal activities; 3) hospitalized, not requiring oxygen; 4) hospitalized, requiring oxygen; 5) hospitalized, requiring high-flow oxygen therapy, or noninvasive ventilation; 6) hospitalized, requiring invasive ventilation; 7) ventilation plus additional organ support such as pressors, renal replacement therapy and ECMO and 8) death.\n\nCOVID Ordinal Scale ranges from 1 to 8, with score 1 on the scale corresponds to an ambulatory patient with minimal symptoms and score 8 on the scale corresponds to death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.8"},{"groupId":"OG001","value":"2.1","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Mortality","description":"All-cause mortality assessed on day 14.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality","description":"All-cause mortality assessed on day 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Inflammatory Marker Between Baseline and 7 Days","description":"Change in marker D-dimer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-197.5","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]}]},{"type":"SECONDARY","title":"COVID Ordinal Scale","description":"COVID ordinal scale","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Not Requiring Supplemental Oxygen","description":"number of participants who received supplemental oxygen or those with supplemental oxygen-free days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Invasive-ventilator","description":"Number of participants who were invasive-ventilator free","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"ICU Stay","description":"Number of participants admitted to ICU","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Inflammatory Marker","description":"Increase in marker Ferritin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"652.5","spread":null},{"groupId":"OG001","value":"381","spread":null}]}]}]},{"type":"SECONDARY","title":"Inflammatory Marker","description":"Increase in marker C-reactive protein","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"165","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":49},"commonTop":[]}}}